Merus N.V. (MRUS)
$22.49
Rating:
Recommendation:
Neutral
| Symbol | MRUS |
|---|---|
| Price | $22.49 |
| Beta | 0.755 |
| Volume Avg. | 0.45M |
| Market Cap | 1.120B |
| Shares () | - |
| 52 Week Range | 12.03-30.81 |
| 1y Target Est | - |
| DCF Unlevered | MRUS DCF -> | |
|---|---|---|
| DCF Levered | MRUS LDCF -> | |
| ROE | -16.83% | Sell |
| ROA | -13.07% | Sell |
| Operating Margin | - | |
| Debt / Equity | 52.41% | Buy |
| P/E | - | |
| P/B | 3.52 | Strong Buy |
Latest MRUS news
About
Download (Excel)Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.